-DOCSTART-	O

Title	O
:	O
[	O
Correlation	O
analysis	O
on	O
changes	O
between	O
cognitive	O
ability	O
and	O
brain	O
fMRI	O
after	O
acupoint	B-I
thread	I-I
embedding	I-I
in	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
patients	I-P
]	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
were	O
assigned	O
to	O
the	O
tested	O
group	O
and	O
the	O
control	O
group	O
in	O
pairing	O
,	O
13	O
in	O
each	O
group	O
.	O

ATE	B-I
was	O
performed	O
in	O
patients	O
of	O
the	O
tested	O
group	O
at	O
Shenmen	O
(	O
HT7	O
)	O
,	O
Fenglong	O
(	O
ST40	O
)	O
,	O
Taixi	O
(	O
KI3	O
)	O
and	O
Zusanli	O
(	O
ST36	O
)	O
acupoints	O
,	O
once	O
every	O
month	O
for	O
6	O
times	O
in	O
total	O
;	O
but	O
for	O
patients	O
of	O
the	O
control	O
group	O
only	O
sham	O
operation	O
was	O
done	O
at	O
the	O
same	O
acupoints	O
.	O

The	O
correlation	O
between	O
cognitive	B-O
ability	I-O
and	O
fMRI	B-O
were	O
assessed	O
by	O
comparing	O
the	B-O
scores	I-O
of	I-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
and	O
Alzhemer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
section	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
,	O
monitored	O
at	O
two	O
time	O
points	O
,	O
namely	O
,	O
in	O
one	O
week	O
before	O
starting	O
treatment	O
and	O
1	O
week	O
after	O
terminating	O
6	O
-	O
month	O
treatment	O
.	O

Furthermore	O
,	O
fMRI	B-O
was	O
detected	O
to	O
obtain	O
the	O
data	O
of	O
the	B-O
cerebral	I-O
blood	I-O
oxygen	I-O
content	I-O
before	O
treatment	O
and	O
6	O
months	O
after	O
completing	O
the	O
6	O
-	O
month	O
therapeutic	O
course	O
.	O

Correlation	O
analysis	O
was	O
conducted	O
on	O
the	O
obtained	O
data	O
using	O
software	O
SPM	O
.	O

-DOCSTART-	O

Title	O
:	O
Melatonin	B-I
fails	O
to	O
improve	O
sleep	O
or	O
agitation	O
in	O
double	O
-	O
blind	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
of	O
institutionalized	B-P
patients	I-P
with	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

Nursing	O
homes	O
in	O
San	O
Diego	O
,	O
CA	O
,	O
metropolitan	O
area	O
.	O

Subjects	O
were	O
patients	B-P
with	I-P
probable	I-P
Alzheimer	I-P
disease	I-P
.	O

Melatonin	B-I
(	O
8	O
.	O
5	O
mg	O
immediate	O
release	O
and	O
1	O
.	O
5	O
mg	O
sustained	O
release	O
)	O
(	O
N	O
=	O
24	O
)	O
or	O
placebo	B-C
(	O
N	O
=	O
17	O
)	O
administered	O
at	O
10	O
:	O
00	O
P	O
.	O
M	O
.	O
for	O
10	O
consecutive	O
nights	O
.	O

The	O
protocol	O
consisted	O
of	O
baseline	O
(	O
3	O
days	O
)	O
,	O
treatment	O
(	O
10	O
days	O
)	O
,	O
and	O
posttreatment	O
(	O
5	O
days	O
)	O
phases	O
.	O

Sleep	B-O
was	O
measured	O
continuously	O
using	O
actigraphy	B-O
.	O

Agitation	B-O
was	O
rated	O
using	O
both	O
the	B-O
Agitated	I-O
Behavior	I-O
Rating	I-O
Scale	I-O
and	O
the	B-O
Cohen	I-O
-	I-O
Mansfield	I-O
Agitation	I-O
Inventory	I-O
.	O

Treatment	O
effects	O
were	O
examined	O
both	O
across	O
the	O
24	O
-	O
hr	O
day	O
and	O
separately	O
by	O
nursing	O
shift	O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
treatment	I-I
of	O
patients	B-P
with	I-P
MCI	I-P
:	O
a	O
48	O
-	O
week	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
subjects	B-P
with	I-P
MCI	I-P
entered	O
a	O
3	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
followed	O
by	O
48	B-I
weeks	I-I
of	I-I
double	I-I
-	I-I
blind	I-I
donepezil	I-I
(	O
5	O
mg	O
/	O
day	O
for	O
6	O
weeks	O
,	O
then	O
10	O
mg	O
/	O
day	O
for	O
42	O
weeks	O
)	O
or	O
placebo	B-C
treatment	I-C
.	O

Primary	O
efficacy	O
variables	O
included	O
change	O
from	O
baseline	O
in	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
Clinical	B-O
Dementia	I-O
Rating	I-O
Scale	I-O
-	I-O
sum	I-O
of	I-O
boxes	I-O
(	I-O
CDR	I-O
-	I-O
SB	I-O
)	I-O
after	O
48	O
weeks	O
of	O
treatment	O
(	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
)	O
.	O

Secondary	O
efficacy	O
measures	O
evaluated	O
cognition	B-O
,	O
behavior	B-O
,	O
and	O
function	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Different	B-I
cholinesterase	I-I
inhibitor	I-I
effects	O
on	O
CSF	O
cholinesterases	O
in	O
Alzheimer	B-P
patients	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
cranial	B-I
electrical	I-I
stimulation	I-I
on	O
sleep	O
disturbances	O
,	O
depressive	O
symptoms	O
,	O
and	O
caregiving	O
appraisal	O
in	O
spousal	B-P
caregivers	I-P
of	I-P
persons	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
eight	I-P
participants	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
active	B-I
CES	I-I
or	O
sham	B-C
CES	I-C
for	O
4	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
delays	O
progression	O
to	O
AD	O
in	O
MCI	B-P
subjects	I-P
with	I-P
depressive	I-P
symptoms	I-P
.	O

METHODS	O
:	O
The	O
study	O
sample	O
was	O
composed	O
of	O
756	B-P
participants	I-P
with	I-P
aMCI	I-P
from	I-P
the	I-P
3	I-P
-	I-P
year	I-P
,	I-P
double	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
-	I-P
controlled	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
Cooperative	I-P
Study	I-P
drug	I-P
trial	I-P
of	I-P
donepezil	I-P
and	I-P
vitamin	I-P
E	I-P
.	O

Beck	B-O
Depression	I-O
Inventory	I-O
(	I-O
BDI	I-O
)	I-O
was	O
used	O
to	O
assess	O
depressive	B-O
symptoms	I-O
at	O
baseline	O
and	O
participants	O
were	O
followed	O
either	O
to	O
the	O
end	O
of	O
study	O
or	O
to	O
the	O
primary	O
endpoint	O
of	O
progression	O
to	O
probable	O
or	O
possible	O
AD	O
.	O

-DOCSTART-	O

Title	O
:	O
Lithium	B-I
trial	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
10	O
-	O
week	O
study	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
71	I-P
patients	I-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
>	I-P
or	I-P
=	I-P
21	I-P
and	I-P
<	I-P
or	I-P
=	I-P
26	I-P
)	I-P
were	O
successfully	O
randomly	O
assigned	O
to	O
placebo	B-C
(	O
N	O
=	O
38	O
)	O
or	O
lithium	B-I
treatment	I-I
(	O
N	O
=	O
33	O
)	O
at	O
6	O
academic	O
expert	O
memory	O
clinics	O
.	O

The	O
10	O
-	O
week	O
treatment	O
included	O
a	O
6	O
-	O
week	O
titration	O
phase	O
to	O
reach	O
the	O
target	O
serum	O
level	O
of	O
lithium	B-I
(	O
0	O
.	O
5	O
-	O
0	O
.	O

8	O
mmol	O
/	O
L	O
)	O
.	O

The	O
primary	O
outcome	O
measures	O
were	O
cerebrospinal	B-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
levels	I-O
of	I-O
phosphorylated	I-O
tau	I-O
(	I-O
p	I-O
-	I-O
tau	I-O
)	I-O
and	O
GSK	B-O
-	I-O
3	I-O
activity	I-O
in	I-O
lymphocytes	I-O
.	O

Secondary	O
outcome	O
measures	O
were	O
CSF	B-O
concentration	I-O
of	I-O
total	I-O
tau	I-O
and	O
beta	B-O
-	I-O
amyloid	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
(	I-O
Abeta	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
)	I-O
,	O
plasma	B-O
levels	I-O
of	I-O
Abeta	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
,	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
-	I-O
Cognitive	I-O
summary	I-O
scores	I-O
,	O
MMSE	B-O
,	O
and	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
.	O

Patients	O
were	O
enrolled	O
in	O
the	O
study	O
from	O
November	O
2004	O
to	O
July	O
2005	O
.	O

-DOCSTART-	O

Title	O
:	O
Atomoxetine	B-I
augmentation	O
of	O
cholinesterase	B-I
inhibitor	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
disease	I-P
:	O
6	O
-	O
month	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
trial	O
study	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
(	O
PLA	O
)	O
-	O
controlled	O
,	O
parallel	O
-	O
groups	O
study	O
,	O
starting	O
with	O
a	O
5	O
-	O
33	O
-	O
day	O
screening	O
and	O
evaluation	O
period	O
,	O
followed	O
by	O
a	O
6	O
-	O
month	O
treatment	O
period	O
.	O

Eight	O
independent	O
or	O
academic	O
outpatient	O
clinics	O
in	O
the	O
United	O
States	O
.	O

Male	B-P
or	I-P
female	I-P
patients	I-P
,	I-P
aged	I-P
55	I-P
years	I-P
and	I-P
older	I-P
,	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
(	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
between	I-P
10	I-P
and	I-P
26	I-P
)	I-P
at	I-P
baseline	I-P
.	O

ATX	B-I
(	O
25	O
-	O
80	O
mg	O
/	O
day	O
)	O
or	O
PLA	B-I
for	O
up	O
to	O
6	O
months	O
,	O
added	O
to	O
ongoing	B-I
cholinesterase	I-I
-	I-I
inhibitor	I-I
therapy	I-I
.	O

Alzheimer	B-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Portion	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
,	O
primary	O
measure	O
)	O
,	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
score	I-O
at	O
end	O
point	O
,	O
Neuropsychiatric	B-O
Inventory	I-O
,	O
and	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
Inventory	I-O
-	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Inventory	I-O
total	I-O
score	I-O
,	O
safety	B-O
measures	I-O
(	O
secondary	O
measures	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effectiveness	O
of	O
donepezil	B-I
in	O
reducing	O
clinical	O
worsening	O
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Data	O
from	O
906	B-P
patients	I-P
(	I-P
388	I-P
receiving	I-P
placebo	I-P
;	I-P
518	I-P
receiving	I-P
donepezil	I-P
)	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
[	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
10	I-P
-	I-P
27	I-P
]	I-P
were	O
pooled	O
from	O
3	O
randomized	O
,	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
studies	O
.	O

Clinical	O
worsening	O
was	O
defined	O
as	O
decline	O
in	O
(	O
1	O
)	O
cognition	B-O
(	O
MMSE	B-O
)	O
,	O
(	O
2	O
)	O
cognition	B-O
and	O
global	B-O
ratings	I-O
(	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
plus	I-O
Caregiver	I-O
Input	I-O
/	O
Gottfries	B-O
-	I-O
Brne	I-O
-	I-O
Steen	I-O
scale	I-O
)	O
or	O
(	O
3	O
)	O
cognition	B-O
,	O
global	B-O
ratings	I-O
and	O
function	B-O
(	O
various	B-O
functional	I-O
measures	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
25	O
-	O
week	O
,	O
open	O
-	O
label	O
trial	O
investigating	O
rivastigmine	B-I
transdermal	I-I
patches	I-I
with	O
concomitant	B-I
memantine	I-I
in	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
post	O
hoc	O
analysis	O
.	O

METHODS	O
:	O
Post	O
hoc	O
analysis	O
of	O
a	O
25	O
-	O
week	O
,	O
randomized	O
,	O
prospective	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
.	O

Patients	O
receiving	O
donepezil	O
were	O
switched	O
to	O
rivastigmine	O
patches	O
(	O
4	O
.	O
6	O
mg	O
/	O
24	O
h	O
)	O
immediately	O
or	O
following	O
a	O
7	O
-	O
day	O
withdrawal	O
for	O
4	O
weeks	O
(	O
core	O
phase	O
)	O
,	O
before	O
titrating	O
up	O
to	O
9	O
.	O
5	O
mg	O
/	O
24	O
h	O
for	O
a	O
further	O
20	O
-	O
week	O
extension	O
phase	O
.	O

Prior	O
memantine	O
therapy	O
was	O
continued	O
throughout	O
.	O

Tolerability	B-O
(	O
adverse	B-O
events	I-O
[	I-O
AEs	I-O
]	I-O
,	O
serious	B-O
AEs	I-O
[	I-O
SAEs	I-O
]	I-O
and	O
discontinuations	B-O
)	O
and	O
efficacy	B-O
(	O
cognition	B-O
,	O
global	B-O
functioning	I-O
and	O
activities	B-O
of	I-O
daily	I-O
living	I-O
[	I-O
ADLs	I-O
]	I-O
)	O
were	O
assessed	O
for	O
the	O
rivastigmine	B-I
transdermal	I-I
patch	I-I
,	O
with	O
or	O
without	O
concomitant	B-I
memantine	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
tarenflurbil	B-I
on	O
cognitive	O
decline	O
and	O
activities	O
of	O
daily	O
living	O
in	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
disease	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
enrolling	O
patients	B-P
with	I-P
mild	I-P
AD	I-P
was	O
conducted	O
at	O
133	O
trial	O
sites	O
in	O
the	O
United	O
States	O
between	O
February	O
21	O
,	O
2005	O
,	O
and	O
April	O
30	O
,	O
2008	O
.	O

Concomitant	O
treatment	O
with	O
cholinesterase	O
inhibitors	O
or	O
memantine	O
was	O
permitted	O
.	O

Tarenflurbil	B-I
,	O
800	O
mg	O
,	O
or	O
placebo	B-C
,	O
administered	O
twice	O
a	O
day	O
.	O

Co	O
-	O
primary	O
efficacy	O
end	O
points	O
were	O
the	O
change	O
from	O
baseline	O
to	O
month	O
18	O
in	O
total	O
score	O
on	O
the	B-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
,	I-O
80	I-O
-	I-O
point	I-O
version	I-O
)	I-O
and	O
Alzheimer	B-O
Disease	I-O
Cooperative	I-O
Studies	I-O
-	I-O
activities	I-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADCS	I-O
-	I-O
ADL	I-O
)	I-O
scale	I-O
.	O

Additional	O
prespecified	O
slope	O
analyses	O
explored	O
the	O
possibility	O
of	O
disease	O
modification	O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
,	O
controlled	O
phase	O
II	O
study	O
of	O
a	B-I
5	I-I
-	I-I
HT6	I-I
receptor	I-I
antagonist	I-I
,	O
SB	B-I
-	I-I
742457	I-I
,	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Participating	B-P
subjects	I-P
had	I-P
a	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
of	I-P
12	I-P
to	I-P
26	I-P
after	I-P
a	I-P
4	I-P
-	I-P
week	I-P
,	I-P
single	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
run	I-P
-	I-P
in	I-P
phase	I-P
,	O
and	O
were	O
randomized	O
(	O
2:1:1	O
:	O
2	O
)	O
to	O
receive	O
placebo	B-C
,	O
SB	B-I
-	I-I
742457	I-I
5	O
mg	O
,	O
15	O
mg	O
,	O
or	O
35	O
mg	O
once	O
daily	O
for	O
24	O
weeks	O
.	O

Coprimary	O
efficacy	O
endpoints	O
were	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
with	I-O
caregiver	I-O
input	I-O
(	I-O
CIBIC	I-O
+	I-O
)	I-O
score	I-O
and	O
change	O
from	O
baseline	O
in	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
score	I-O
at	O
Week	O
24	O
,	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
.	O

A	O
model	O
-	O
based	O
design	O
provided	O
90	O
%	O
power	O
to	O
detect	O
a	O
linear	O
trend	O
in	O
treatment	O
response	O
across	O
increasing	O
doses	O
and	O
>	O
or	O
=90	O
%	O
power	O
to	O
compare	O
SB	B-I
-	I-I
742457	I-I
35	O
mg	O
with	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
aerobic	B-I
exercise	I-I
on	O
mild	O
cognitive	O
impairment	O
:	O
a	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Six	O
-	O
month	O
,	O
randomized	O
,	O
controlled	O
,	O
clinical	O
trial	O
.	O

Veterans	O
Affairs	O
Puget	O
Sound	O
Health	O
Care	O
System	O
clinical	O
research	O
unit	O
.	O

Thirty	B-P
-	I-P
three	I-P
adults	I-P
(	I-P
17	I-P
women	I-P
)	I-P
with	I-P
amnestic	I-P
mild	I-P
cognitive	I-P
impairment	I-P
ranging	I-P
in	I-P
age	I-P
from	I-P
55	I-P
to	I-P
85	I-P
years	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
70	I-P
years	I-P
)	I-P
.	O

Intervention	O
Participants	O
were	O
randomized	O
either	O
to	O
a	B-I
high	I-I
-	I-I
intensity	I-I
aerobic	I-I
exercise	I-I
or	O
stretching	B-C
control	I-C
group	O
.	O

The	B-I
aerobic	I-I
group	O
exercised	O
under	O
the	O
supervision	O
of	O
a	O
fitness	O
trainer	O
at	O
75	O
%	O
to	O
85	O
%	O
of	O
heart	O
rate	O
reserve	O
for	O
45	O
to	O
60	O
min	O
/	O
d	O
,	O
4	O
d	O
/	O
wk	O
for	O
6	O
months	O
.	O

The	O
control	O
group	O
carried	O
out	O
supervised	B-C
stretching	I-C
activities	I-C
according	O
to	O
the	O
same	O
schedule	O
but	O
maintained	O
their	O
heart	O
rate	O
at	O
or	O
below	O
50	O
%	O
of	O
their	O
heart	O
rate	O
reserve	O
.	O

Before	O
and	O
after	O
the	O
study	O
,	O
glucometabolic	B-O
and	O
treadmill	B-O
tests	I-O
were	O
performed	O
and	O
fat	B-O
distribution	I-O
was	O
assessed	O
using	O
dual	B-O
-	I-O
energy	I-O
x	I-O
-	I-O
ray	I-O
absorptiometry	I-O
.	O

At	O
baseline	O
,	O
month	O
3	O
,	O
and	O
month	O
6	O
,	O
blood	O
was	O
collected	O
for	O
assay	B-O
and	O
cognitive	B-O
tests	I-O
were	O
administered	O
.	O

Performance	O
measures	O
on	O
Symbol	B-O
-	I-O
Digit	I-O
Modalities	I-O
,	O
Verbal	B-O
Fluency	I-O
,	O
Stroop	B-O
,	O
Trails	B-O
B	I-O
,	O
Task	B-O
Switching	I-O
,	O
Story	B-O
Recall	I-O
,	O
and	O
List	B-O
Learning	I-O
.	O

Fasting	B-O
plasma	I-O
levels	I-O
of	I-O
insulin	I-O
,	O
cortisol	B-O
,	O
brain	B-O
-	I-O
derived	I-O
neurotrophic	I-O
factor	I-O
,	O
insulinlike	B-O
growth	I-O
factor	I-O
-	I-O
I	I-O
,	O
and	O
beta	B-O
-	I-O
amyloids	I-O
40	I-O
and	O
42	B-O
.	O

-DOCSTART-	O

Title	O
:	O
11	O
C	O
-	O
PiB	O
PET	O
assessment	O
of	O
change	O
in	O
fibrillar	O
amyloid	O
-	O
beta	O
load	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
treated	O
with	O
bapineuzumab	B-I
:	O
a	O
phase	O
2	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
ascending	O
-	O
dose	O
study	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
intravenous	B-I
bapineuzumab	I-I
or	O
placebo	B-C
in	O
a	O
ratio	O
of	O
seven	O
to	O
three	O
in	O
three	O
ascending	O
dose	O
groups	O
(	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
or	O
2	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Each	O
dose	O
group	O
was	O
enrolled	O
after	O
safety	O
review	O
of	O
the	O
previous	O
group	O
.	O

Randomisation	O
was	O
by	O
interactive	O
voice	O
response	O
system	O
;	O
masking	O
was	O
achieved	O
with	O
numbered	O
kit	O
allocation	O
.	O

Patients	O
,	O
investigators	O
,	O
study	O
site	O
personnel	O
,	O
sponsor	O
staff	O
,	O
and	O
carers	O
were	O
masked	O
to	O
treatment	O
.	O

Patients	O
received	O
up	O
to	O
six	O
infusions	O
,	O
13	O
weeks	O
apart	O
,	O
and	O
had	O
(	O
11	O
)	O
C	O
-	O
PiB	O
PET	O
scans	O
at	O
baseline	O
and	O
at	O
weeks	O
20	O
,	O
45	O
,	O
and	O
78	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
difference	O
between	O
the	B-I
pooled	I-I
bapineuzumab	I-I
group	O
and	O
the	B-C
pooled	I-C
placebo	I-C
group	O
in	O
mean	O
change	O
from	O
screening	O
to	O
week	O
78	O
in	O
(	B-O
11	I-O
)	I-O
C	I-O
-	I-O
PiB	I-O
cortical	I-O
to	I-O
cerebellar	I-O
retention	I-O
ratio	I-O
averaged	I-O
across	I-O
six	I-O
cortical	I-O
regions	I-O
of	I-O
interest	I-O
.	O

Analysis	O
was	O
by	O
modified	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
with	O
EudraCT	O
,	O
number	O
2004-004120-12	O
;	O
ISRCTN17517446	O
.	O

-DOCSTART-	O

Title	O
:	O
Spine	B-I
Surgery	I-I
under	O
general	B-I
anesthesia	I-I
may	O
not	O
increase	O
the	O
risk	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
We	O
searched	O
the	O
Clinical	O
Data	O
Repository	O
of	O
the	O
University	O
of	O
Virginia	O
for	O
patients	B-P
receiving	I-P
spine	I-P
surgery	I-P
from	I-P
January	I-P
1	I-P
,	I-P
1992	I-P
to	I-P
March	I-P
1	I-P
,	I-P
2004	I-P
.	O

Patients	B-P
with	I-P
newly	I-P
-	I-P
diagnosed	I-P
AD	I-P
after	I-P
the	I-P
surgery	I-P
but	I-P
before	I-P
March	I-P
1	I-P
,	I-P
2009	I-P
(	I-P
a	I-P
minimal	I-P
5	I-P
-	I-P
year	I-P
follow	I-P
-	I-P
up	I-P
time	I-P
after	I-P
the	I-P
surgery	I-P
)	I-P
were	O
identified	O
.	O

